Compare XPEL & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | ABCL |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2019 | 2020 |
| Metric | XPEL | ABCL |
|---|---|---|
| Price | $39.72 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 227.5K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | 10.91 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $476,200,000.00 | $75,128,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | $25.44 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | 13.27 | ★ 160.56 |
| 52 Week Low | $24.27 | $1.89 |
| 52 Week High | $55.91 | $6.52 |
| Indicator | XPEL | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 41.86 |
| Support Level | $35.10 | $2.75 |
| Resistance Level | $55.36 | $3.84 |
| Average True Range (ATR) | 1.37 | 0.15 |
| MACD | 0.61 | -0.02 |
| Stochastic Oscillator | 64.11 | 6.96 |
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.